# US 8,278,265 B2 · Methods, kits and compositions comprising crotamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,265 B2
- Document ID: US8278265B2
- Status: Granted
- Kind: B2
- Application number: 11/902,064
- Filed: 2007-09-18
- Published: 2008-07-31
- Granted: 2012-10-02
- Earliest claimed: 2005-03-18
- Assignees: Fundacao De Amparo A Pesquisa Do Estado De Sao Paulo -- Fapesp.
- Inventors: Tetsuo Yamane; Irina Kerkis; Alexandre Kerkis; Gandhi Rádis Baptista; Mirian Akemi Furuie Hayashi; Katsuhiro Konno; Alvaro Rossan B. P. Da Silva; Lygia da Veiga Pereira; Eduardo Brandt De Oliveira
- Web page: https://patentgrep.com/patent/US8278265B2

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0047: {Green fluorescent protein [GFP]}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 14/46: from vertebrates
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention refers to uses of crotamine and compositions containing it, based on its characteristic of interaction with genetic material. Under submicromolar quantities, the polypeptide is no longer toxic, presenting the characteristics properties of cell penetration, transport of molecules to the surface, cytoplasm or cell nucleus and particularly, selective cell penetration. The invention also refers to compositions comprising a pharmaceutically effective concentration of crotamine and its use for the treatment of diseases and dysfunctions, based on its characteristics of interaction with genetic material, such as DNA and RNA, and cell selectivity. Further, the invention refers to a kit comprising crotamine as a reagent to: (i) transfect or carry molecules to the surface, cytoplasm or nucleus of the cell or (ii) identify and select actively proliferating cells in a homogeneous and/or mixed cell population, particularly the ones originated from the umbilical cord and/or bone marrow and others undifferentiated cells such as progenitors and stem cells from different sources of organism and cancer cells.

## Claims

### Claim 1

A composition comprising a conjugate of crotamine consisting of SEQ ID No. 1 and a pharmaceutically effective compound for treating cancer, wherein:
(i) aa1-3 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-carried polar amino acid residues;
(ii) aa5-10 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-polar amino acid residues;
(iii) aa12-17 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, acid amino acid residues and non-polar amino acid residues;
(iv) aa19-29 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, acid amino acid residues, non-carried polar amino acid residues and non-polar amino acid residues;
(v) aa31-35 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-polar amino acid residues; and
(vi) aa38-42 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, non-carried polar amino acid residues and non-polar amino acid residues,
wherein the crotamine is present in an amount of 100 μM to 0.1 μM effective for the delivery of the pharmaceutically effective compound into cells.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein crotamine is present in an amount of about 1 μM to about 0.1 μM.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein crotamine further provides selectivity over actively proliferating cells.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein it is a pharmaceutical composition used for the treatment of dysfunctions, deficiencies and/or diseases related to cell proliferation.

### Claim 5 (depends on 1)

The composition according to claim 1 for identifying or labeling cells amongst a homogeneous and/or a mixed cell population.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein:
(a) said basic amino acid residues are selected from the group consisting of: Lys, His, and Arg;
(b) said non-carried polar amino acid residues are selected from the group consisting of Gln, Ser, and Tyr;
(c) said non-polar amino acid residues are selected from the group consisting of Gly, Ile, Leu, Met, Phe, Pro, Trp; and
(d) said acid amino acid residues are selected from the group consisting of Asp, and Glu.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein:
(a) said basic amino acid residues and said non-carried polar amino acid residues in aa1-3 of SEQ ID No. 1 are Tyr, Lys, and Gln;
(b) said basic amino acid residues and said non-polar amino acid residues in aa5-10 of SEQ ID No. 1 are His, Lys, Lys, Gly, Gly, His;
(c) said basic amino acid residues, acid amino acid residues and said non-polar amino acid residues in aa12-17 of SEQ ID No. 1 are Phe, Pro, Lys, Glu, Lys, Ile;
(d) said basic amino acid residues, acid amino acid residues, non-carried polar amino acid residues and said non-polar amino acid residues in aa19-29 of SEQ ID No. 1 are Leu, Pro, Pro, Ser, Ser, Asp, Phe, Gly, Lys, Met, Asp;
(e) said basic amino acid residues and said non-polar amino acid residues in aa31-35 of SEQ ID No. 1 are Arg, Trp, Arg, Trp, Lys; and
(f) said basic amino acid residues, non-carried polar amino acid residues and said non-polar amino acid residues in aa38-42 of SEQ ID No. 1 are Lys, Lys, Gly, Ser, and Gly.

### Claim 8 (depends on 7)

The composition according to claim 7 wherein the amino acid sequence of said SEQ ID No. 1 consists of SEQ ID No. 2.
